Paclitaxel does not cause central nervous adverse effects: A prospective vigilance-controlled EEG mapping study in ovarian cancer patients

Wiener Klinische Wochenschrift

Volumn 112, Issue 23, 2000, Pages 1007-1013

  Mayerhofer, K ^a   Bodner, K ^a   Saletu, B ^a   Bodner Adler, B ^a   Anderer, P ^a   Hefler, L ^a   Kaider, A ^a   Leodolter, S ^a   Kainz, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Central nervous adverse effects; EEG; Neurotoxicity; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ALPHA RHYTHM; ARTICLE; ATTENTION; BETA RHYTHM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; PSYCHOMETRY; SHORT TERM MEMORY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROUSAL; ATTENTION; BRAIN; BRAIN MAPPING; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; FEMALE; HUMANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 0034619997     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: A phase I-II study
2. Taxol in ovarian cancer
3. Promotion of microtubule assembly in vitro by taxol
4. Taxol as a second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy
5. Peripheral neurotoxicity of Taxol in patients previously treated with Cisplatin
6. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat
7. Transient encephalopathy after paclitaxel (Taxol) infusion
8. Aritfact processing in topographic mapping of electroencephalographic activity in neuropsychopharmacology
9. Restriction to a limited set of EEG-target variables may lead to misinterpretation of pharmaco-EEG results
10. Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls
11. Reporting results of cancer treatment
12. Topographic brain mapping of EEG in neuropsychopharmacology - Part I. Methodological aspects
13. Test-retest reliability of spectral parameters of the EEG
14. Nonorganic insomnia in generalized anxiety disorders. 2. Comparative studies on sleep, awakening daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods
15. Comparative study for assessing quality of life of patients with exogenous sleep disorders (temporary sleep onset and sleep interruption disorders) treated with hops-valerian preparation and a benzodiazepine drug
16. Noopsychological changes and psychopathological characteristics of HIV-1 patients of various risk groups
17. The conception of nervous and mental energy. II. Vigilance: A physiological state of the nervous system
18. Quality of life during chemotherapy for small cell lung cancer
19. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
20. A phase 1 trial of taxol given by a 6- hour intravenous infusion
21. Phase I study of paclitaxel in patients with recurrent malignant glioma: A north american brain tumor consortium report
22. Acute encephalopathy: A new toxicity associated with high-dose paclitaxel